While their study is systematic and follows PRISMA guidelines, it does not focus on autoimmune diseases and does not consider the most clinically relevant outcome measures for autoimmune diseases, such as CDAI (for CD) and DAS28‐CRP (for RA). The gene discussed is CRP; the disease is rheumatoid arthritis.